未名醫藥(002581.SZ):向100名激勵對象授予1963.46萬份股票期權
格隆匯12月23日丨未名醫藥(002581.SZ)公佈,《山東未名生物醫藥股份有限公司2024年股票期權激勵計劃(草案)》規定的授予條件已經成就,根據山東未名生物醫藥股份有限公司2024年第四次臨時股東大會的授權,公司於2024年12月20日召開第五屆董事會第三十一次會議及第五屆監事會第二十一次會議,審議通過了《關於向公司2024年股票期權激勵計劃激勵對象授予股票期權的議案》,同意以2024年12月20日為股票期權授予日,以12.35元/股的行權價格向符合授予條件的100名激勵對象授予1,963.46萬份股票期權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.